GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...
GSK Up Over 7%, On Track for Largest Percent Increase Since December 2022 — Data Talk
--On pace for largest percent increase since Dec. 6, 2022, when it rose 7.85% --Down 51.37% from its all-time closing high of $76.92 on Jan. 6, 1999 ...
FiercePharma2h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK Stock Up On Q4 Results, Positive Outlook; Plans To Buyback GBP 2 Bln Shares
Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...
GSK launches $2.5 bln buyback, lifts sales target after stellar Q4
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook — 2nd Update
GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.